Thierry Conroy
Impact in
Papers in
- Co-authors
- Olivier Bouché (32 shared papers)Michel Pierre Ducreux (36 shared papers)Marc Ychou (24 shared papers)Antoine Adenis (27 shared papers)Pierre Michel (9 shared papers)S. Gourgou-Bourgade (9 shared papers)Y. Bécouarn (10 shared papers)Laurent Bedenne (21 shared papers)
- Journals
- European Journal of Cancer (31 papers)Annals of Oncology (25 papers)Journal of Clinical Oncology (22 papers)Quality of Life Research (12 papers)Health and Quality of Life Outcomes (7 papers)
- Partner nations
- FranceUnited KingdomNetherlands
In The Last Decade
Thierry Conroy
242 papers receiving 27k citations
Thierry Conroy's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 18.3k
- Surgery 4.1k
- Pulmonary and Respiratory Medicine 2.6k
- Cancer Research 737
- Geriatrics and Gerontology 123
Countries citing papers authored by Thierry Conroy
This map shows the geographic impact of Thierry Conroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thierry Conroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thierry Conroy more than expected).
Fields of papers citing papers by Thierry Conroy
This network shows the impact of papers produced by Thierry Conroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thierry Conroy. The network helps show where Thierry Conroy may publish in the future.
Co-authors
The 25 scholars most cited alongside Thierry Conroy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 260 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Hit paper breakdown → | 2011 | 6279 |
| 2 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer Hit paper breakdown → | 2018 | 2184 |
| 3 | Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial Hit paper breakdown → | 2011 | 1656 |
| 4 | Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203 Hit paper breakdown → | 2006 | 1395 |
| 5 | Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2015 | 1071 |
| 6 | Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102 Hit paper breakdown → | 2007 | 939 |
| 7 | Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 872 |
| 8 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis Hit paper breakdown → | 2016 | 757 |
| 9 | Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 Hit paper breakdown → | 2010 | 617 |
| 10 | 2004 | 443 | |
| 11 | 2012 | 394 | |
| 12 | 1997 | 383 | |
| 13 | 2009 | 352 | |
| 14 | 2003 | 341 | |
| 15 | Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial Hit paper breakdown → | 2014 | 334 |
| 16 | Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2023 | 329 |
| 17 | 1991 | 328 | |
| 18 | 2012 | 324 | |
| 19 | Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial Hit paper breakdown → | 2012 | 285 |
| 20 | 1998 | 265 |
About Thierry Conroy
Thierry Conroy is a scholar working on Oncology, Surgery, Management Science and Operations Research, Pulmonary and Respiratory Medicine and Statistics and Probability, having authored 260 papers that have together received 27.7k indexed citations. Recurring topics across this work include Cancer survivorship and care (60 papers), Pancreatic and Hepatic Oncology Research (56 papers), Colorectal Cancer Surgical Treatments (34 papers), Colorectal Cancer Treatments and Studies (34 papers), Esophageal Cancer Research and Treatment (28 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers), Psychometric Methodologies and Testing (13 papers) and Gastric Cancer Management and Outcomes (9 papers). The work is most often cited by research in Oncology (18.3k citations), Surgery (4.1k citations), Pulmonary and Respiratory Medicine (2.6k citations), Cancer Research (737 citations) and Geriatrics and Gerontology (123 citations). Thierry Conroy has collaborated with scholars based in France, United Kingdom and Netherlands. Frequent co-authors include Olivier Bouché, Michel Pierre Ducreux, Marc Ychou, Antoine Adenis, Pierre Michel, S. Gourgou-Bourgade, Y. Bécouarn, Laurent Bedenne, Jean‐Luc Raoul and C. Montoto-Grillot. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, Quality of Life Research and Health and Quality of Life Outcomes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.